ARS Pharmaceuticals Files 8-K on New Agreement and Obligation
Ticker: SPRY · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1671858
| Field | Detail |
|---|---|
| Company | Ars Pharmaceuticals, Inc. (SPRY) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $250.0 million, $100.0 million, $25.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
ARS Pharma just signed a new deal and took on debt. Details TBD.
AI Summary
On September 29, 2025, ARS Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement and a direct financial obligation. The filing indicates the company entered into a new agreement and incurred a financial obligation, though specific details of the agreement and obligation are not provided in this excerpt.
Why It Matters
This filing signals a significant new development for ARS Pharmaceuticals, potentially involving new partnerships, financing, or operational commitments that could impact its future business strategy and financial standing.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and a direct financial obligation, which could represent significant new commitments or risks for the company.
Key Players & Entities
- ARS Pharmaceuticals, Inc. (company) — Registrant
- September 29, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 11682 El Camino Real, Suite 300 (address) — Principal executive offices
- San Diego, California (location) — Principal executive offices location
- Silverback Therapeutics, Inc. (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by ARS Pharmaceuticals, Inc. on September 29, 2025?
The provided excerpt does not specify the details of the material definitive agreement, only that one was entered into.
What is the nature of the direct financial obligation or off-balance sheet arrangement created by ARS Pharmaceuticals, Inc.?
The excerpt states that a direct financial obligation or an obligation under an off-balance sheet arrangement was created, but does not provide specific details.
What is the principal executive office address for ARS Pharmaceuticals, Inc.?
The principal executive office address is 11682 El Camino Real, Suite 300, San Diego, California, 92130.
When was ARS Pharmaceuticals, Inc. incorporated?
ARS Pharmaceuticals, Inc. was incorporated in Delaware.
What was the former name of ARS Pharmaceuticals, Inc.?
The former name of ARS Pharmaceuticals, Inc. was Silverback Therapeutics, Inc., with a name change date of April 12, 2016.
Filing Stats: 1,326 words · 5 min read · ~4 pages · Grade level 11.1 · Accepted 2025-09-29 16:15:28
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SPRY The Nasdaq
- $250.0 million — to (the "Lenders"), providing for up to $250.0 million of term loans from the Lenders to the B
- $100.0 million — was advanced in the principal amount of $100.0 million on September 29, 2025 ("Closing Date").
- $25.0 million — "Term B Loan") in a principal amount of $25.0 million may be advanced at the Borrower's elect
Filing Documents
- d27880d8k.htm (8-K) — 34KB
- d27880dex101.htm (EX-10.1) — 740KB
- 0001193125-25-223228.txt ( ) — 1069KB
- spry-20250929.xsd (EX-101.SCH) — 3KB
- spry-20250929_lab.xml (EX-101.LAB) — 18KB
- spry-20250929_pre.xml (EX-101.PRE) — 11KB
- d27880d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit Number Description 10.1#* Credit Agreement, dated September 29, 2025, by and between ARS Pharmaceuticals Operations, Inc., as the borrower, ARS Pharmaceuticals, Inc. and certain of its subsidiaries from time to time party thereto as guarantors, the lenders from time to time party thereto, and RA Capital Agency Services, LLC, as administrative agent and collateral agent for the lenders. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). # Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. * Certain information in this exhibit is omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type that the registrant treats as private or confidential.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARS PHARMACEUTICALS, INC. Date: September 29, 2025 By: /s/ Richard Lowenthal Richard Lowenthal, M.S., MSEL President and Chief Executive Officer